Role of Gut Microbiome in the Health Benefits
BEEROTA18
1 other identifier
interventional
20
1 country
1
Brief Summary
Beneficial effects of moderate chronic consumption of beer have been extensively reported, however, the mechanisms have not been elucidated yet. Gut microbiota is an important mediator in the homeostasis of the host. Polyphenols act as bacterial substrates and modulators of the gut microbiota. Indeed, the investigators have previously observed that the chronic moderate consumption of red wine by metabolic syndrome patients triggered in an amelioration of the metabolic syndrome variables, and this effect was mediated, at least partially, by the interaction of the gut microbiota with the polyphenols of the red wine. In this manner, beer has a medium content of polyphenols. Thus, the investigators propose that the beneficial effects of moderate chronic consumption of beer could be because of the action of the gut microbiota with the beer polyphenols. The investigators are going to perform an intervention study in which normal volunteers will consume three different beer types with different content in polyphenols and it will be analyzed the gut microbiota profile (Metagenomics), metabolites (Metabolomics) and metabolic syndrome markers (gene expression, ELISA) to establish the correspondent relationships, trying to decipher the implication of the gut microbiota in the beneficial effects of moderate chronic consumption of beer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2019
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 13, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 19, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2020
CompletedFirst Submitted
Initial submission to the registry
March 8, 2022
CompletedFirst Posted
Study publicly available on registry
March 29, 2022
CompletedMarch 29, 2022
March 1, 2022
4 months
March 8, 2022
March 17, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in gut microbiota
change from baseline in 16S rRNA amplicons determined in DNA from feces after 6 weeks
Baseline, 2nd, 4th and 6th weeks visits
Secondary Outcomes (6)
Change in caloric consumption
Baseline and 6th weeks visits
Change in waist circumference
Baseline and 6th weeks visits
Change in glucose concentration
Baseline and 6th weeks visits
Change in HDL-cholesterol concentration
Baseline and 6th weeks visits
Change in triglycerides concentration
Baseline and 6th weeks visits
- +1 more secondary outcomes
Study Arms (1)
Normal population
OTHER20 participants representing a normal population will include a daily beer in their meals, changing the kind of beer every 2 weeks from alcohol-free lager beer, lager beer, or dark beer.
Interventions
A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
Eligibility Criteria
You may qualify if:
- Age \> 18 years
- Usual consumer of Beer
You may not qualify if:
- being a non usual beer-consumer,
- body mass index (BMI) \> 40 kg m2.
- acute or chronic infection, inflammatory disease or endocrine disorders; history of cancer; leukocytosis; anti-inflammatory, corticosteroid or hormone treatment.
- history of alcohol abuse or drug dependence.
- under a restrictive diet or a weight change ≥5 kg during the 3 months prior to the study.
- antibiotic therapy, prebiotics, probiotics, synbiotics, vitamin supplements or any other medical treatment influencing intestinal microbiota during the 3 months before the start of the study or during the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Universitario Virgen de la Victoria
Málaga, 29010, Spain
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Francisco J. Tinahones, PhD
Instituto de Investigacion Biomedica de Malaga
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 8, 2022
First Posted
March 29, 2022
Study Start
February 13, 2019
Primary Completion
June 19, 2019
Study Completion
December 30, 2020
Last Updated
March 29, 2022
Record last verified: 2022-03